CEVIMELINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CEVIMELINE HYDROCHLORIDE (CEVIMELINE HYDROCHLORIDE).
Cevimeline is a muscarinic cholinergic agonist that binds to M1 and M3 receptors, stimulating salivary gland secretion.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes CYP2C19 and CYP3A5 metabolism. |
| Excretion | Cevimeline is primarily eliminated via renal excretion (approximately 80% of the dose as unchanged drug and metabolites) and biliary/fecal excretion (approximately 20%). |
| Half-life | The terminal elimination half-life is approximately 3–4 hours in patients with normal renal function, supporting three-times-daily dosing. |
| Protein binding | Approximately 20% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Volume of distribution is approximately 1.2 L/kg, indicating extensive extravascular distribution into tissues. |
| Bioavailability | Absolute oral bioavailability is approximately 30–40% due to first-pass metabolism. |
| Onset of Action | Following oral administration, clinical effects (increased saliva production) begin within 30–60 minutes. |
| Duration of Action | Duration of action is approximately 3–4 hours per dose, necessitating three-times-daily dosing for sustained sialogogic effect. |
30 mg orally three times daily. May increase to 60 mg three times daily if needed.
| Dosage form | CAPSULE |
| Renal impairment | No specific adjustment required; use caution in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Contraindicated. |
| Pediatric use | Not FDA approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment, but consider age-related renal decline and potential for increased anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CEVIMELINE HYDROCHLORIDE (CEVIMELINE HYDROCHLORIDE).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Caution should be exercised; consider developmental benefits of breastfeeding vs. mother's need for drug. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, cevimeline caused reduced fetal weight and increased skeletal variations at doses 0.1 times the maximum recommended human dose. No adequate human studies. Risk cannot be ruled out; use only if benefit justifies potential risk. First trimester: unknown risk. Second/third trimesters: unknown risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Uncontrolled asthma","Narrow-angle glaucoma","Acute iritis"]
| Precautions | ["Use with caution in patients with cardiovascular disease, asthma, chronic bronchitis, COPD, cholelithiasis, nephrolithiasis, or biliary tract disorders; may cause visual disturbances including decreased visual acuity, especially at night; contraindicated in patients with uncontrolled asthma, narrow-angle glaucoma, or acute iritis."] |
| Food/Dietary | No significant food interactions; however, high-fat meals may delay absorption. Avoid excessive caffeine as it may exacerbate side effects like tachycardia. |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of excessive cholinergic effects (e.g., bradycardia, hypotension, bronchospasm) in mother. Fetal monitoring as per standard obstetric care; no specific fetal monitoring required. |
| Fertility Effects | No human data on fertility effects. In animal studies, cevimeline did not impair fertility at clinically relevant doses. |
| Clinical Pearls |
| Cevimeline is a muscarinic agonist with higher affinity for M3 receptors, making it effective for xerostomia in Sjögren's syndrome. Avoid in patients with uncontrolled asthma, narrow-angle glaucoma, or iritis. Monitor for excessive sweating and bradycardia. Can be combined with pilocarpine but increase vagal tone risk. |
| Patient Advice | Take with or without food, but taking after meals may reduce nausea. · Avoid driving or operating machinery if you experience blurred vision or dizziness. · Drink plenty of water to prevent dehydration from sweating. · Report symptoms like slow heart rate, chest pain, or difficulty breathing immediately. · Do not stop abruptly; consult your doctor for dose adjustments. |